Recent studies have suggested that prevention of obesity and non-alcoholic fatty liver disease (NAFLD) should start with maternal dietary management. We previously reported disrupted methionine cycle, associated with NAFLD, in male offspring liver due to maternal high-fat (HF) diet, thus we hypothesize that maternal one-carbon supplement may reduce the risk of NAFLD in offspring via the normalizing methionine cycle. To test it, female mice (F0) were exposed to either a maternal normal-fat diet (NF group) a maternal HF diet (HF group), or a maternal methyl donor supplement (H1S or H2S group) during gestation and lactation. The offspring male mice (F1) were exposed to a postweaning HF diet to promote NAFLD. While the HF offspring displayed obesity, glucose intolerance and hepatic steatosis, the H1S and H2S offspring avoided hepatic steatosis. This phenotype was associated with the normalization of the methionine cycle and the restoration of L-carnitine and AMPK activity. Furthermore, maternal HF diet induced epigenetic regulation of important genes involved in fatty acid oxidation and oxidative phosphorylation via DNA methylation modifications, which were recovered by maternal one-carbon supplementation. Our study provides evidence that maternal one-carbon supplement can reverse/block the adverse effects of maternal HF diet on promoting offspring NAFLD, suggesting a potential nutritional strategy that is administered to mothers to prevent NAFLD in the offspring.
1 December 2020 in Oncology and Translational Medicine
Objective: To identify the differences in clinical features and outcomes between cancer survivors and non-cancer patients with coronavirus disease 2019 (COVID-19). Methods: In this multicenter, retrospective, and observational cohort study from February 10, 2020 to March 31, 2020 in Wuhan, China, all cancer survivors infected with COVID-19 were screened, and statistically matched with non-cancer patients with COVID-19 using propensity score matching. Demographic, clinical, treatment, and laboratory data were extracted from a standardized medical recording system and underwent review and assessment. Results: Sixty-one cancer survivors and 183 matched non-cancer patients were screened from 2,828 COVID-19 infected patients admitted to 4 hospitals in Wuhan, China. The median ages of the cancer survivor cohort and non-cancer patient cohort were 64.0 (55.0-73.0) and 64.0 (54.0-73.5), respectively (P = 0.909). Cancer survivors reported a higher incidence of symptom onset than non-cancer patients. Fever (80.3% vs. 65.0%; P = 0.026) was the most prevalent symptom, followed by cough (65.6% vs. 37.7%; P < 0.001), myalgia, and fatigue (45.9% vs. 13.6%; P < 0.001). The risks of the development of severe events (adjusted hazard ratio [AHR] = 1.25; 95% confidence interval [CI]: 0.76-2.06; P = 0.378) and mortality (relative risk [RR] = 0.90, 95% CI: 0.79-1.04; P = 0.416) in the cancer survivor cohort were comparable to those of the matched non-cancer patient cohort. However, the cancer survivor cohort showed a higher incidence of secondary infection (52.5% vs. 30.1%; RR = 1.47, 95% CI: 1.11-1.95; P = 0.002) and a prolonged viral RNA shedding duration (32 days [IQR 26.0-46.0] vs.24.0 days [IQR 18.0-33.0]; AHR = 0.54; 95% CI: 0.38-0.80; P < 0.05). Conclusion: Compared to non-cancer patients, cancer survivors with COVID-19 exhibited a higher incidence of secondary infection, a prolonged period of viral shedding, but comparable risks of the development of severe events and mortality. It is helpful for clinicians to take tailored measures to treat cancer survivors with COVID-19.